Full-Time

Senior Associate Scientist

Protein Science

Posted on 11/11/2024

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

Biotechnology
Healthcare

Junior, Mid, Senior

Cambridge, MA, USA

Category
Lab & Research
Life Sciences
Requirements
  • M.S. or B.S. with a minimum of 2 years of relevant experience, industry experience preferred
  • Hands-on experience and knowledge of protein purification using HIC, IEX, SEC and affinity chromatography. Experience with GE AKTA FPLC is preferred.
  • Excellent lab technique and the ability to work independently to analyze, interpret, and present data
  • Proficiency in biochemical and biophysical characterization methods (e.g. ELISA, DSC, DSF, SDS-PAGE, BLI, SPR, SEC-MALS, flow cytometry) is desired
  • Ability to multi-task to support multiple projects across platform discovery organization
  • Ability to work in a highly collaborative, team-based environment
  • Excellent written and verbal communication skills
Responsibilities
  • Perform a range of biochemical techniques such as ELISA, MSD, Western blotting, SDS-PAGE, and flow cytometry to characterize protein expression and function.
  • Perform a range of biophysical techniques such as surface plasmon resonance (SPR), biolayer Interferometry (BLI), size-exclusion chromatography – multiangle light scattering (SEC-MALS), and differential scanning calorimetry (DSC) or fluorimetry (DSF) to characterize protein-ligand interactions and protein stability.
  • Assist to analyze and interpret data from biophysical assays to understand binding kinetics, thermodynamics, and binding affinities.
  • Assist to troubleshoot and optimize assays as needed to improve sensitivity, specificity, and reproducibility.
  • Maintain accurate and up-to-date laboratory records.
  • Routinely present updates at group meetings

Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This technology allows for the delivery of large amounts of genetic material to particular tissues, aiming for long-lasting effects from a single dose. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce these treatments at scale, potentially reaching hundreds of millions of doses. Unlike many competitors, Generation Bio's approach allows for redosing, meaning that treatments can be adjusted over time to meet patient needs. The company's goal is to make genetic medicine more accessible and to address significant medical needs in the population.

Company Stage

IPO

Total Funding

$252.9M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

1%

1 year growth

-21%

2 year growth

-14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaboration with Moderna boosts development and market entry potential.
  • Non-viral platform aligns with safety trends, increasing demand for Generation Bio's tech.
  • Reorganization extends cash runway, supporting long-term sustainability and investor confidence.

What critics are saying

  • 40% workforce reduction may impact innovation and strategic execution.
  • Lease termination could lead to legal or financial distractions.
  • Financial constraints might limit future R&D investments.

What makes Generation Bio unique

  • Generation Bio's iqDNA evades immune detection, unlike traditional gene therapies.
  • Their ctLNP system offers targeted delivery, enhancing treatment precision.
  • RES manufacturing allows scalable production, supporting broad treatment access.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE